Briefing
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
A retrospective analysis of a personalized tumor-informed ctDNA assay on prospectively collected samples was used to monitor treatment in advanced melanoma. The abstract does not name the manufacturer.
- Design: Evidence level 3
- Assay: Not named in the abstract